Skip to content
value.today

Shuttle Pharmaceuticals Holdings, Inc.

SHPH
$3 Mmarket cap on Aug 1, 2026-66.7% since Jan 2024
Compare
World rank
#27,383
Revenue
—
For year ending December-2025
Net income
$-12 M
SEC filing
Employees
—

Shuttle Pharmaceuticals Holdings, Inc. in brief

Shuttle Pharmaceuticals Holdings, Inc. is a listed company in the Biotechnology industry, based in Gaithersburg, Maryland, USA. Its market value was $3 M on 1 August 2026, which makes it the 27,383rd largest listed company in the world and the 4,464th largest in the USA on this site. Ryan Trasolini is its chief executive. Its shares trade under the symbol SHPH (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Shuttle Pharmaceuticals Holdings, Inc.

On November 21, 2025, we acquired substantially all of the assets and liabilities of Molecule.ai, a pharmaceutical software company building an artificial intelligence driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development. The platform is engineered to accelerate the iteration cycles that characterize modern drug discovery while preserving scientific reproducibility, traceability and operational reliability. Molecule.ai adapts state of the art AI algorithms to create a practical, domain-specific AI infrastructure layer for molecular research and development. We will seek to leverage Molecule.ai’s molecular modeling and predictive analytics platform to significantly augment our drug discovery and development business purpose. In tandem with the Molecule.ai asset acquisition, on November 20, 2025, we committed to a plan to wind-down our clinical trials of Ropidoxuridine, our lead product candidate.

From the company's annual report filed with the US SEC: read the report

Shuttle Pharmaceuticals Holdings, Inc. timeline

2 events, 2019–2022
  1. 2019
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2022
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 31 August 2022; shares registered for exchange trading on 29 August 2022.

Events of Shuttle Pharmaceuticals Holdings, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$8 M$15 M$23 M$30 M2023202420252026

World rank over time

▲ up 4,068 places since 2022
2022-12-25: #27966#27,96620222023-07-30: #31014#31,01420232024-01-05: #31373#31,37320242026-03-08: #13385#13,38520262026-08-01: #23898#23,8982026

Rank in USA: #5,112 (Dec 2022) · #5,363 (Jul 2023) · #4,534 (Jan 2024) · #2,469 (Mar 2026) · #4,158 (Aug 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.3×
Free cash flow yield
-186.7%
Net margin
—
Operating margin
—
Return on equity
-520.9%
Liabilities / assets
78.4%
Net debt
$-0M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue —, net income $-1M—FY21Fiscal year ending Dec 2022: revenue —, net income $-5M—FY22Fiscal year ending Dec 2023: revenue —, net income $-7M—FY23Fiscal year ending Dec 2024: revenue —, net income $-9M—FY24Fiscal year ending Dec 2025: revenue —, net income $-12M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-12M$-12M—
Dec 2024——$-8M$-9M—
Dec 2023——$-6M$-7M—
Dec 2022——$-2M$-5M—
Dec 2021——$-2M$-1M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-9M——$-7.16—
Dec 2024$-7M——$-82.60—
Dec 2023$-6M$0M$-6M$-3.53—
Dec 2022$-3M——$-5.04—
Dec 2021$-0M————

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-4M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-2M—Dec ’24Three months to Mar 2025: revenue —, net income $-3M—Mar ’25Three months to Jun 2025: revenue —, net income $-4M—Jun ’25Three months to Sep 2025: revenue —, net income $-2M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-3M—Dec ’25Three months to Mar 2026: revenue —, net income $-2M—Mar ’26Three months to Jun 2026: revenue —, net income $-3M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Shuttle Pharmaceuticals Holdings, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-12 M
Net income
$-12 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$10 M
Total liabilities
$8 M
Total equity
$2 M

As of December-2025

Top 5 institutional investors in Shuttle Pharmaceuticals Holdings, Inc.#

As of Sep 30, 2026
5 institutions held 41,772 shares (about 0.9% of the shares outstanding) on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 5 largest institutional investors in Shuttle Pharmaceuticals Holdings, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Jane Street Group, LLC19,445New0.41%$0 MNov 12, 2026
2Geode Capital Management, LLC14,715New0.31%$0 MNov 6, 2026
3UBS Group AG5,730New0.12%$0 MNov 10, 2026
4Tower Research Capital LLC (TRC)1,762+1,373 (+352.96%)0.04%$0 MNov 16, 2026
5Kelleher Financial Advisors1200 (0.00%)0.00%$0 MOct 30, 2026

Insider trading at Shuttle Pharmaceuticals Holdings, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$182 K
6 purchases, 1 insider
Sold, 12 months
$505 K
5 sales, 1 insider
Net, 12 months
-$323 K
open market only
Insiders on file
12
since
$111 K-$505 K$0Dec 2023: bought $0 (0 trades), sold $3 K (2 trades)Dec 23Jun 2026: bought $111 K (2 trades), sold $0 (0 trades)JunJul 2026: bought $71 K (4 trades), sold $505 K (5 trades)Jul
Bought (open market)Sold (open market)Hover a month for the totals
Shuttle Pharmaceuticals Holdings, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed HRT Financial LP10% ownerSell-82,116$4.480$368 K0Form 4
filed HRT Financial LP10% ownerSell-1,033$4.670$5 K60,238Form 4
filed HRT Financial LP10% ownerBuy+731$3.110$2 K61,271Form 4
filed HRT Financial LP10% ownerBuy+8,266$3.380$28 K60,540Form 4
filed HRT Financial LP10% ownerSell-18,531$3.520$65 K52,274Form 4
filed HRT Financial LP10% ownerSell-10,580$3.330$35 K70,805Form 4
filed HRT Financial LP10% ownerSell-9,022$3.510$32 K81,385Form 4
filed HRT Financial LP10% ownerBuy+7,851$3.540$28 K90,407Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Shuttle Pharmaceuticals Holdings, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
14,956
7.4% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-06-10 23:50 UTC, code T1, resumed 13:00 UTC
  • 2025-10-10 15:43 UTC, code LUDP, resumed 15:48 UTC
  • 2025-10-10 15:03 UTC, code LUDP, resumed 15:13 UTC
  • 2025-10-10 14:56 UTC, code LUDP, resumed 15:01 UTC
  • 2025-07-15 19:57 UTC, code LUDP, resumed 20:00 UTC

Fails to deliver

  • : 2,944 shares at $5.24
  • : 358 shares at $5.21
  • : 2,322 shares at $5.05
  • : 3,929 shares at $4.86
  • : 19 shares at $4.91

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Shuttle Pharmaceuticals Holdings, Inc. scorecard#

Passes 0 of the 6 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-7.16 vs -82.60Diluted EPS -7.16 in fiscal 2025 against -82.60 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$12 MNet income -$12 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-791.9%-791.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.1×Current ratio 0.06 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Shuttle Pharmaceuticals Holdings, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Shuttle Pharmaceuticals Holdings, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021
Income statement
Research and development4,0553,6193,5171,047r1,022
General and administrative5,6731,3931,047474r37
Operating expenses11,9177,6965,8922,344r1,743
Total costs and expenses2,4002,100100——
Operating income−11,917−7,696−5,892−2,344r−1,743
Interest and finance income1.13879——
Interest expense and finance costs——2,1239183.8
Net interest income—100100r——
Other non-operating income (expense)195−1,449−700−2,652r591
Income before tax——−6,593−4,996r−1,152
Net income including minority interests—−9,540—1,688—
Net income attributable to shareholders−11,722−9,145−6,593−4,996r−1,152
Earnings per share, basic-7.16-79.65r-3.53r-5.04r-0.12
Earnings per share, diluted-7.16-82.60r-3.53r-5.04r—
Shares, weighted average (basic)1.60.1r1.9r1.3r9.3
Shares, weighted average (diluted)1.60.1r1.9r1.3r—
Balance sheet
Cash and cash equivalents3341,9202,5768,417505
Short-term investments——2,887——
Other current assets169291——4.9
Current assets5032,2115,5938,578510
Property, plant and equipment1719251319
Right-of-use (leased) assets10227633456117
Other intangible assets9,841————
Total assets10,4762,5065,9528,654652
Accounts payable1,454597———
Customer deposits——6.5——
Current liabilities7,9671,5341,0429762,217
Lease liabilities (non-current)155238304—62
Total liabilities8,2221,7971,8969762,280
Retained earnings−46,300−34,578−25,433r−18,841r−13,845r
Shareholders' equity2,2547094,056r7,678−1,764r
Total liabilities and equity10,4762,5065,9528,654652
Shares outstanding0.2r0.2r2.0r1.7r9.3
Cash-flow statement
Depreciation and amortization2905.5———
Share-based compensation933260182238r910
Cash from operating activities−9,482−7,327−5,581−2,666r−300
Capital expenditure——−19——
Cash from investing activities−3,0572,916−2,830——
Debt repaid—−60———
Shares issued—3,993—10,022—
Cash from financing activities10,9523,7552,57010,579r688
Change in cash−1,586−656−5,8417,912388
Report10-K10-K10-K10-K/A10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Shuttle Pharmaceuticals Holdings, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Auditor changedFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Auditor changed 2 · Restructuring 1 · Acquisition or sale completed 3 · Directors and officers 8 · Material agreement 10 · Agreement ended 2 · Unregistered share sale 6 · Shareholder rights changed 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 1

Shuttle Pharmaceuticals Holdings, Inc.: events reported to the SEC
FiledWhat happenedFiling
Auditor changed8-K
Auditor changed8-K
Unregistered share sale8-K
Shareholder vote8-K
Material agreement8-K
Delisting notice8-K
Acquisition or sale completed8-K/A
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Acquisition or sale completedMaterial agreementUnregistered share sale8-K
RestructuringMaterial agreementAgreement ended8-K
Delisting notice8-K
Material agreementUnregistered share sale8-K
Material agreementAgreement ended8-K
Material agreement8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Shuttle Pharmaceuticals Holdings, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2026$10 MPrivate placement after listing$2 to $10 million47equity, optionsSEC
Nov 2025$3 MPrivate placement after listing$2 to $10 million1optionsSEC
Jun 2025$4 MPrivate placement after listing$2 to $10 million1equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Shuttle Pharmaceuticals Holdings, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2025–2025
Latest
—
2025-11-20
Shuttle Pharmaceuticals Holdings, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025············—
Shuttle Pharmaceuticals Holdings, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Shuttle Pharmaceuticals Holdings, Inc. compares in Biotechnology

  • Market cap$3 M · higher than 2% of 726
  • Price / book1.3× · lower than 71% of 534
  • FCF yield-186.7% · higher than 2% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Shuttle Pharmaceuticals Holdings, Inc.🇺🇸$3 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Shuttle Pharmaceuticals Holdings, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Shuttle Pharmaceuticals Holdings, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Shuttle Pharmaceuticals Holdings, Inc.? Suggest a correction